Monday, 18 Jun 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
09 May 2018 News Tocilizumab Beats Anti-TNFs for Treatment Retention
09 May 2018 Social AbbVie Submits Biologics License Application to FDA for Risankizumab (IL-23 Mab) for Moderate to Severe Plaque Psoriasis
08 May 2018 Social FDA has approved 9 biosimilars in the USA> Zarxio, Inflectra, Erelzi, Amjevita, Renflexis, Cyltezo, Ixifi; Mvasi (Avastin), Ogivri (Herceptin). There are 5 more biosimilars (of either filgrastim or herceptin) in front of FDA w/ upcoming PDUFA dates
03 May 2018 Social Sandoz biosimilar version of rituximab set back by a complete response letter from the FDA delaying development of their RTX biosimilar; same recent fate as Celltrions RTX biosimilar.
24 Apr 2018 News FDA Arthritis Panel Split on the Efficacy and Safety of Baricitinib in RA
16 Apr 2018 Slide of the day 23 FDA Approved Biologics for Use in Rheumatology
11 Apr 2018 Social Shingrix captured 90% of shingles vaccine market, w/ greater efficacy & CDC endorsement, plus is NOT a live vaccine & could be used with biologics. While cost is the same, it has more nuisance side effect & no studies/data in RA, CTD.
09 Apr 2018 Social 2015 US Pharma donated $116 million to Pt advocacy groups. For example Patients for Biologics Safety & Access (who opposes biosimilar substitution and includes Crohn’s & Colitis, Arthritis & Lupus Foundations) accepted $9.1 million from drug companies
05 Apr 2018 News IL-6 Inhibition Most Effective in Polycyclic Systemic JIA
05 Apr 2018 News Rituximab May Halt ILD in Antisynthetase Syndrome Myositis
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%).
27 Mar 2018 News Anakinra May Attenuate Stroke Outcomes
09 Mar 2018 News FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
06 Mar 2018 News Abatacept Efficacy in JIA
22 Feb 2018 Social of Derm mtg in San Diego has several new biologic therapies of Atopic Dermatitis, including baricitinib, upadacitinib, ASN002 (JAK/SYK inhibitor) and anti IL-33 (ANB020).
22 Feb 2018 Social FDA grants "breakthrough" status to Pfizers Xeljanz (tofacitinib) for phase III trials in atopic dermatitis
19 Feb 2018 Social Correction: 2018 AAD presentations on upadacitinib (Abbvies JAK1 inhibitor) in moderate to severe atopic dermatitis shows improvements in pruritus at week 1 and improvement in the extent and severity of skin lesions at week 2.
14 Feb 2018 News Abatacept Improves GvHD Outcomes
12 Feb 2018 Social RT @uptoTate: Switching to biosimilars are non inferior in IBD. Dr. U. Mahadevan #RWCS @RheumNow
11 Feb 2018 ACR Video Dr. George Martin: New Molecular Therapies in Metastatic Melanoma